CTOs on the Move


 
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aeglea.com
  • 221 Crescent Street, Building 17 Suite 102B
    Waltham, MA USA 02453
  • Phone: 512.942.2935

Executives

Name Title Contact Details

Similar Companies

QUATRx Pharmaceuticals Company

QUATRx Pharmaceuticals Company is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSciConcepts

BioSciConcepts is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Su International

Su International is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BellBrook Labs

BellBrook Labs is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Somatic Therapies

Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.